1. Introduction
===============

Worldwide, cervical cancer is the fourth most common and lethal cancer worldwide. It is the second most commonly diagnosed cancer and third leading cause of cancer death among females in less-developed countries. According to the World Health Statistics 2012, it was estimated that there were 527,600 new cervical cancer cases and 265,700 deaths worldwide in 2012.^\[[@R1]\]^ Although the incidence of cervical cancer decreases in countries with screening program, a large proportion of those diagnosed with invasive cancer have locally advanced disease at presentation. The concept of locally advanced cervical cancer (LACC) was established and defined in the 90s of the 20th century, especially for stage Ib2 in general and bulky stage Ib2 to IIa2 in particular (the local tumor diameter \>4 cm). After radical hysterectomy, although the 5-year survival rate for patient with early stage (stage Ia--Ib1) cervical cancer may become as high as 80%--90%,^\[[@R2],[@R3]\]^ the 5-year survival rate was decreased to about 60% for stage Ib2 to IIa.^\[[@R4]\]^ However, the radical surgery is limited to patients with International Federation of Gynecology and Obstetrics (FIGO) IIa or earlier stage. Patients with advanced disease (FIGO stage Ib2 and above) usually undergo traditional treatment such as radiation therapy instead of primary surgery due to bulky lesion foci, local hemorrhage, inflammatory necrosis, and parametrial invasion. Although radiation therapy can have similar efficacy as surgery, the damage to surrounding tissues caused by radiation may lead to loss of ovarian function and sexual capacity, which can significantly impact the quality of life.

At present, there is still a controversy on the treatment of LACC. Most patients with LACC are treated with radiotherapy and/or chemotherapy. Neoadjuvant chemotherapy (NACT) prior to primary surgical intervention is also being used increasingly in the management of LACC in many countries. The 2015 NCCN Guideline suggested the chemoradiation (CRT) to be the standard treatment in LACC (Category 1). The results of 18 trials from 11 countries showed clear evidence that adding chemotherapy to radiotherapy improves both overall and disease-free survival. For the trials in which CRT alone was used, there was a 6% absolute survival benefit and an 8% disease-free survival benefit at 5 years.^\[[@R5],[@R6]\]^ Recently, NACT has been reported useful in the control of LACC. Early or prechemotherapy NACT has been used to reduce tumor volume prior to surgery or radiotherapy. For patients with advanced cervical cancer, 2 to 3 cycles, NACT can improve the success rate of resection. Previous studies show that NACT can inhibit tumor micrometastases and enhance the resection rate by shrinking tumor volume.^\[[@R7],[@R8]\]^ A meta-analysis showed that NACT followed by radical hysterectomy can improve the survival rate.^\[[@R9]\]^ However, a recent phase III GOG trial failed to demonstrate any survival benefit. It may be due to a variety of clinical and biological factors, and the use of different chemotherapeutic regimens based on cisplatin.^\[[@R8]\]^ Currently there is no standard neoadjuvant chemotherapy regimen. The regimens often used include:^\[[@R10]\]^ TP (TAX+DDP), VAC (VCR+ADM+CTX), and GP (GEM+DDP). The safety and efficacy of paclitaxel plus platinum (TP) as NACT have been demonstrated in many literatures.^\[[@R11]\]^

This prospective study enrolled 61 patients with stage Ib2 and IIa2 LACC (tumor diameter \>4 cm). The efficacy and safety of NACT in treatment of LACC had been demonstrated in our preliminary study.^\[[@R12]\]^ We also found that the TP used for treating NACT following radical hysterectomy had a better short-term efficacy than the direct radical hysterectomy alone. The short-term efficacy of TP regimen treatment of LACC had significant variations and the prognosis was closely related to the short-term efficacy and the follow-up treatment. This intention of this study is to find factors that may be able predict response to the NACT treatment of LACC by further analyzing the clinical and pathological data.

2. Materials and methods
========================

2.1. Participants
-----------------

This prospective study enrolled 61 patients. All the subjects had histologically confirmed cervical cancer (including squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma) undergoing paclitaxel plus platinum as NACT followed by radical hysterectomy. The treatment was performed at the Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. All the participants signed informed consents before the chemotherapy initiation. The enrolled patients also satisfied the following additional criteria: age ≤65 years; FIGO Stage Ib2 and IIa2; tumor diameter \> 4 cm (by vaginal pelvic examination and CT or MRI); and scheduled to have 2 to 3 cycles of chemotherapy. The stage of each patient was determined according to the cervical cancer clinical stage criteria set by the FIGO. The exclusion criteria were: patients with severe complications cannot tolerate surgery or chemotherapy; there are clear distant metastasis (CT or MRI was performed before and after chemotherapy to evaluation); patients with cardiovascular, cerebrovascular, liver, kidney, hematopoietic system, and other serious diseases which affect the 5 years survival; there is uncontrolled epilepsy, central nervous system disorders, or a history of mental disorders; patients with a history of other malignant diseases; patients who have received cytotoxic chemotherapy, radiotherapy, or immune therapy. Evaluation of the clinical response was performed after 2 to 3 cycles of chemotherapy followed radical hysterectomy.

2.2. Chemotherapy
-----------------

The NACT regimen is a platinum-based combined chemotherapy. The patients triaged to receive the TP regimen were randomly assigned into 2 groups: artery intervention (AI) group and intravenous (IV) group. The TP regimen for the AI group is: 60 mg/m^2^ of paclitaxel and 60 mg/m^2^ of cisplatin on day 1, every 10 to 14 days for 1 to 3 cycles. Using a standard Seldinger technique, the left femoral arteries were punctured under local anesthesia, and the bilateral internal iliac arteries were selectively catheterized by a contralateral approach. Once the access to both internal iliac arteries was gained, 5-French catheters (Roberts uterine catheter, COOK) were positioned with the tip in the 0.5 cm before the upper and lower branch of uterine artery. The bilateral branches of uterine artery were displayed by digital subtraction angiography (DSA). The average dose of chemotherapy drugs was injected into the bilateral uterine artery, respectively, embolization with PVA particles as appropriate.

The TP regimen for the IV group is: 135 to 175 mg/m^2^ of median paclitaxel on day 1, AUC5 of carboplatin calculated according to creatinine clearance, every 21 to 28 days for 1 to 3 cycles. The operation was performed 10 to 14 days after the last chemotherapy. Piver III surgery was performed for all the patients after chemotherapy (radical hysterectomy and pelvic lymphadenectomy + double salpingectomy ± double ovariectomy, ovary biopsy was performed to rule out ovarian metastasis before ovary reservation). Evaluation of the chemotherapy response was performed by 2 gynecological oncologists to evaluate the size of each patient\'s cervical tumor and the lymph nodes before the initial chemotherapy and at 10--14 days after the completion of the final cycle of chemotherapy. The tumor size was assessed as the product of the transverse diameter and anterior-posterior diameter measured by pelvic examination and colposcopy. The short axis of the node was measured by CT or MRI.

2.3. Observation standard
-------------------------

### 2.3.1. Clinical data

The data collected include the general medical information (age, menopause, childbirth, family history of cancer, and the surgical methods), tumor stage, tumor type, chemotherapy ways, the cycles of chemotherapy, the prechemotherapy SCCA values, and the chemotherapy-related adverse events. Two CTs were performed, 1 before and 1 after the chemotherapy to exclude distant metastasis or indeed nodal involvement.

### 2.3.2. Pathological results

The pathological data collected include histopathologic result, cell differentiation, cervical invasion, vascular invasion, lymph node involvement (LNI), parametrial infiltration, and margin status. The results were checked by 2 pathologists in our hospital together.

### 2.3.3. Histological response

Histological response was evaluated according to the criteria defined by the Japan Society for Cancer Therapy.^\[[@R13]\]^ The responses were classified into 4 levels: Level 0, almost no treatment-induced tumor degeneration or necrosis; Level 1, degeneration, necrosis, or liquefaction of fewer than two-thirds of the cancer cells; Level 2, marked degeneration, necrosis, liquefaction, or disappearance of more than two-thirds of the cancer cells; and Level 3, necrosis, liquefaction, disappearance or replacement by granulation tissues or fibrosis of the entire tumor. In this study, all the patients were classified into 2 groups: histological responders, including patients with Level 2 and Level 3 response, and histological nonresponders, including patients with Level 0 and Level 1 response. All pathological paraffin sections were examined. The consensus was reached by the same 2 senior pathologists after hysterectomy and before chemotherapy.

2.4. The short-term efficacy as defined by RECIST
-------------------------------------------------

The clinical remission was evaluated according to the World Health Organization (WHO) criteria---The Response Evaluation Criteria in Solid Tumors (RECIST).^\[[@R14]\]^ The complete response (CR) is defined as disappearance of all target lesions, and any pathological lymph nodes (whether target or nontarget) must have reduction in the short axis to \< 10 mm. The partial remission (PR) is defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The progressive disease (PD) is defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest on study). In addition, the relative increase of more or new lesion is also considered as progression). The stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, in reference to the smallest sum diameters during the study. The patients with CR or PR are classified as clinical responders, and the patients with stable disease and progression of disease are defined as clinical nonresponders. If the 2 oncologists reached different conclusions, the results will be rechecked and discussed to reach a consensus.

2.5. Follow-up
--------------

All the patients were followed-up to December 31, 2015. All the recurrence and death data were recorded (see following Figure 1 Study Flow-Chart;).

2.6. Statistical methods
------------------------

SPSS version 18.0^\[[@R15]\]^ was used for statistical analysis. Categorical variables were compared using the Chi-square and Fisher\'s exact tests. Descriptive analysis is presented for median age, clinical stage, tumor size at diagnosis, and the number of chemotherapy cycles. A *P*-value of \<.05 was considered as significant.

3. Result
=========

3.1. General characteristics of NACT in treatment of LACC
---------------------------------------------------------

During the follow-up, no patient existed in PD (disease progression) group in our study. There was no significant difference between other short-term efficacy groups (CR, PR and SD) for patients' age, menopause, childbirth and oncology history (*P* \> .05) (see Table [1](#T1){ref-type="table"}).

###### 

The patients' general characteristic of NACT in the treatment of LACC.
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3.2. The short-term efficacy of NACT in treatment of LACC
---------------------------------------------------------

NACT in treatment of LACC has local effect. The total efficacy of NACT was 91.8% (CR plus PR). The cervical invasion (≤½) was 82.4% in the CR group, 46.2% in the PR group, and 20.0% in the SD group. The difference was statistically significant (*P = *.012). The percentage of tumor regression level 3 (TRG3) in CR group was 29.4%, which was higher than in the PR (2.5%) and in the SD (20.0%) groups. The percentage of tumor regression level 0 (TRG0) in CR group was 41.2%, which was lower than in the PR (82.1%) and in the SD (80.0%) groups. All the slides of surgical specimens were reviewed and classified according to the Tumor Regression Grade (TRG). The good response represents the good short-term efficacy, the difference was statistically significant (*P = *.042). In the different short-term efficacy groups (CR, PR and SD), There was no significant difference between parametrium invasion, margin status, LNI and Lymph vascular space invasion (LVSI) (*P \> *.05) (see Table [2](#T2){ref-type="table"}).
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The primary outcomes of NACT in the treatment of LACC.
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3.3. Predictors of response to NACT in LACC
-------------------------------------------

The route of administration NACT delivery affected its efficacy in the short-term LACC treatment. The AI (97.8%) was significantly more effective than IV (75.1%, *P = *.011). However, no significant different efficacy was found between different tumor stage, tumor size, cell differentiation, tumor type, pathology type, prechemotherapy SCCA values, and chemotherapy cycles (*P \> *.05). (See Table [3](#T3){ref-type="table"})

###### 

The predictors of response to NACT in the treatment of LACC.
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3.4. Adverse events and follow-up
---------------------------------

Gastrointestinal reaction, myelosuppression, and alopecia were mainly NACT chemotherapy-related adverse events in accordance with the Common Terminology Criteria for Adverse Events version 4 (CTCAE v4).^\[[@R16]\]^ The adverse events were rare in AI compared to IV NACT chemotherapy in treatment of LACC, The difference was significant (see Table [4](#T4){ref-type="table"}). Gastrointestinal reaction, Myelosuppression and Alopecia above degree 3 was 0% (0/15), 2/15 (13.3%), 2/15 (13.3%), respectively, in 3 cycles chemotherapy compared to 0% (0/34), 0% (0/34), 8.8% (3/34), respectively, in 2 cycles chemotherapy and 0% (0/12), 0% (0/12), 0% (0/12), respectively, in 1 cycle chemotherapy. So multiple cycles chemotherapy may increase the side effects. All patients were followed-up to the last day of 2015. The median follow-up time was 21.5 months. Out of the 61 patients referred for NACT in LACC, 2 patients were relapse (3.3% recurrence) and 1 patient died from the disease (1.6% mortality).

###### 

NACT treatment-related adverse events.
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4. Discussion
=============

The treatment of stage Ib2 and IIa2 LACC (tumor diameter \> 4 cm) is controversial. The 2009 FIGO^\[[@R17]\]^ guideline indicated that treatment of LACC include: directly radiotherapy concurrent chemotherapy (Level A evidence); radical hysterectomy and bilateral pelvic lymph node dissection, plus adjuvant radiotherapy postoperative (Level C evidence); radical hysterectomy after NACT, and supplementary radiotherapy post-operation (Level B evidence). In 2015, the NCCN guidelines^\[[@R18]\]^ indicated that treatment of LACC including: radical radiotherapy and chemotherapy (Level 1 evidence); (ii) radical hysterectomy and bilateral pelvic lymph node dissection, plus adjuvant radiotherapy postoperation (Level 2B evidence); concurrent chemoradiotherapy supplementary hysterectomy (Level 3 evidence). Some report^\[[@R10]\]^ showed that the efficacy of radical operation and radiotherapy were the same in the treatment of LACC, while others^\[[@R19]\]^ showed that the efficiency of NACT was as high as 53% to 94%. The TRG1 was 10% to 13.8%. In our preliminary retrospective study, with more than 140 LAAC patients enrolled, it clearly showed the high efficacy and safety of paclitaxel plus platinum as NACT following radical surgery in treatment of LACC with low incidence of adverse reactions when compared to direct operation.^\[[@R12]\]^ After the NACT preoperation, the tumor size, the metastasis rate of lymph node, the rates of LVSI, and parametrial infiltration decreased.^\[[@R20],[@R21]\]^ In order to create a good condition to eliminate subclinical lesions, the dissemination intraoperation and metastasis after operation was reduced. This led to the observation of the lower tumor recurrence and higher survival rate, which were consistent with other literature report.^\[[@R22],[@R23]\]^ Preoperation NACT can be easily observed and evaluated for the sensitivity of the tumor to chemotherapeutic drugs and can be used to guide the next stage treatment. According to the sensitivity of the preoperation therapy, the postoperation chemotherapy may not need to be adjusted or even required. But clinical efficacy is only a superficial observation. It can reflect the progression of the disease in some instance. The pathological outcomes are the main risk factors to the prognosis of the NACT treatment for the LACC. The main pathological outcomes include LVSI, LNI, depth of tumor invasion, parametrial invasion, resection margin, etc. The lager and deeper of the tumor, the more number and higher layer of LNI, the higher incidence rate of LVSI. These risk factors for the prognosis of cervical cancer could be used to directly predict the prognosis and efficacy of NACT in treatment of LACC.^\[[@R8]\]^

For the 61 patients with NACT preoperation in the study, the short-term efficacy is 91.8%, including 27.9% in CR, 63.9% in PR, and 8.2% remained in SD. There was no patient in the progression (PD) group. The Observed pathologic outcomes of NACT showed that the number of tumor invasion depth ≤1/2 and the tumor regression in the efficacy groups (CR and PR) were obviously higher than that in the SD group (*P = *.012 and .042). In terms of resection status and parametrial infiltration, there were no significant differences for LVSI and LNI between the different short-term efficacy groups (*P \> *.05). Considering the effect of NACT in the treatment of LACC was mainly local that can significantly reduce the size, the myometrial invasion, and the local regression of the tumor for the NACT sensitive patients. However, the significant tumor regression may not indicate the improved potential risk in metastasis, including LNI, LVSI and parametrial infiltration that might be caused by the differences of pathogenesis between the primary tumor and the metastasis.

It has been reported that the therapeutic effect of chemotherapy was closely related to the blood supply to the tumor. The efficacy of chemotherapy was better for multi-blood supply tumor with high drug concentration in local area than that for less-blood supply tumor with low drug concentration in the local area.^\[[@R24]\]^ Adachi et al^\[[@R25]\]^ comparing the AI with IV NACT in the treatment of LACC and found that the drug concentration of local area in AI group was 2.8 times higher than that in IV group. This stronger tumor killing ability was mainly because the drugs were injected directly into the surrounding area of the tumors via AI, avoiding the chemotherapy first pass through the kidney and liver that can reduce the probability of drug plasma protein binding. It could also because that the arterial embolization can be used to reduce the blood supply to the tumor, promoting the tumor tissue ischemia, hypoxia and necrosis, and then reduce the spread of the tumor through blood. Our study showed that how the chemotherapy was given had major influence to the short-term NACT efficacy. The clinical effective rate in the AI group (97.8%) was significantly higher than that in the IV group (75.1%), (*P = *.011), regardless of the tumor stage, differentiation degree, tumor type, pathological type, chemotherapy cycles, tumor diameter and pre-operation SCCA values. However multi-cycle chemotherapy showed higher optimal short-term efficacy for the patients with tumor diameter ≤ 5 cm. Two and 3 cycles of chemotherapy had the optimal efficacy of up to 90% (94.1% in 2 cycles and 100% in 3 cycles), which was higher than that of one cycle chemotherapy about 70% (9/12). However, multiple cycles of chemotherapy may increase the side effects. This study showed that for patients with LACC treated with 2-cycles AI treatment NACT can achieve the desired local therapeutic efficacy. Chemotherapy-related adverse events including gastrointestinal reaction, myelosuppression and alopecia in the AI group were significantly rarer than that in the IV group.

In our study, the median follow-up time was 21.5 months. Out of the 61 patients referred for NACT in LACC, 2 patients were relapse (3.3% recurrence) and 1 patient died from the disease (1.6% mortality). For patients with malignant tumor, tumor free survival (DFS) and overall survival (OS) are important indicators of the efficacy. There was a large sample NACT treatment study^\[[@R23]\]^ that compared the long-term survival rate of neoadjuvant chemotherapy followed by radical hysterectomy to the radical surgery only and concurrent chemoradiotherapy. For the 476 patients enrolled with cervical cancer stage Ib2∼IIb, the 3 years disease-free survival rates were 85.0%, 77.4%, and 52.9%, respectively, and the 5 year survival rates were 88.7%, 80.2% and 64.4%, respectively. It showed that NACT can significantly improve the long-term survival rate of LACC.

5. Conclusion and limitation
============================

In conclusion, this study showed that NACT comprised TP for LACC treatment has significant local effect. The NACT could reduce tumor myometrial invasion and regress tumor, but had little effect to reduce the potential tumor metastasis. Around 91.8% of participants had either CR or PR by RECIST after undergoing NACT. A significantly higher response rate and lower adverse event rate were observed in the AI group than that in the IV group. Patients with tumor diameter ≤ 5 cm that received multiple cycles of chemotherapy had better short-term efficacy. It was found that 2 cycles of NACT by AI treatment to the LACC can get the desired short-term efficacy with low chemotherapy adverse events. Due to the short follow-up time of this study, it cannot answer the questions of OS and DFS. Further study with larger sample size (in order to find more events) is needed to answer the long-term survival questions
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